Company Profile
Nexsen is a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural, and biosecurity applications. The company offers Group B Streptococcus (GBS) rapid sensor, a diagnostic for the detection of human GBS in expectant mothers.
Its portfolio also includes kidney diseases, a POC tests for the screening, detection, and ongoing monitoring of various subsets of acute kidney injury and chronic kidney disease, bovine mastitis, a farm diagnostic to detect mastitis early which helps farmers, and biosecurity pathogen tests, a portable sensor for frontline detection of invasive pests and pathogens -built for customs officers, farmers, and quarantine zones. The company was incorporated in 2021 and is based in Sydney, Australia.